法国生物技术公司Aqemia近日获得了3000万欧元的A轮追加融资，这将使得其A轮融资总额达到6000万欧元。这家总部位于巴黎的公司，利用生成式人工智能和量子计算技术，致力于加速新药物的发现和设计。
据悉，本轮融资由Wendel Growth领投，现有投资者包括法国风险投资公司Eurazeo、公共银行Bpifrance和Elaia参投。Aqemia开发的人工智能技术，能够快速推进分子的发现和设计，这些分子有望成为对抗各种疾病的新药物。
Aqemia的技术引起了广泛关注，因为它有望改变药物开发的缓慢和昂贵的过程。该公司表示，其人工智能驱动的技术可以大大缩短药物研发的时间，并降低成本。
“我们的技术正在改变药物发现和设计的游戏规则，”Aqemia的首席执行官说。”我们相信，通过这种创新的方法，我们可以更快地开发出新的药物，以帮助患者。”
According to a report by Sifted, Aqemia’s AI-driven technology is expected to accelerate the discovery and design of molecules that could become new drugs to combat various diseases. The additional funding will enable the company to further develop and expand its operations.
The company’s approach to drug development has attracted attention because it has the potential to change the slow and expensive process of drug discovery. Aqemia claims that its AI-driven technology can significantly reduce the time and cost of developing new drugs.
“Our technology is changing the rules of the game in drug discovery and design,” said the CEO of Aqemia. “We believe that with this innovative approach, we can develop new drugs faster to help patients.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 0